Trials / Completed
CompletedNCT00069277
Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors
A Phase I Dose-Finding Study of E7389 (Halichondrin B Analog) Administered Once Every Three Weeks in Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The malignancies (advanced solid tumors) that have been chosen for evaluation of E7389 are those where E7389 has demonstrated significant pre-clinical anti-tumor activity, both in vitro and in vivo. The ultimate goal is to demonstrate the clinical activity of E7389 in the treatment of these, and potentially other, tumor types.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E7389 |
Timeline
- Start date
- 2003-08-01
- Primary completion
- 2005-04-01
- Completion
- 2005-04-01
- First posted
- 2003-09-24
- Last updated
- 2012-04-11
- Results posted
- 2012-02-09
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00069277. Inclusion in this directory is not an endorsement.